Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial

European Heart Journal

Volumn 32, Issue 12, 2011, Pages 1500-1508

  Zhang, Yuquing ^a,b   Zhang, Xuezhong ^a,b   Liu, Lisheng ^a,b   Zanchetti, Alberto ^c  

^a FUWAI HOSPITAL   (China)

^b Beijing Hypertension League Institute   (China)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Antihypertensive therapy; Cardiovascular disease; Elderly; Stroke; Systolic blood pressure; Trials

Indexed keywords

FELODIPINE; GENERIC DRUG; HYDROCHLOROTHIAZIDE; PLACEBO;

AGE DISTRIBUTION; ARTICLE; CHINESE; DEATH; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; HYPERTENSION; LOW DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FELODIPINE; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 79959468267     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr039     Document Type: Article

References (31)

1. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield M, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, StruiJker-Boudier HA, Zanchetti A. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25: 1105-1187. (Pubitemid 46924065)
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252. (Pubitemid 37553153)
4. Whitworth JA;World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-1992. (Pubitemid 38296854)
5. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should SBP be lowered? A critical reappraisal. J Hypertens 2009;27:923-934.
6. Liu L, Zhang Y, Liu G, Zhang X, Zanchetti A; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005;23:2157-2172. (Pubitemid 41666745)
7. Zhang Y, Zhang X, Liu L, Zanchetti A, for the FEVER Study Group. Effects of individual risk factors and total risk stratification on the incidence of cardiovascular events in a population of treated Chinese patients with hypertension. Data from the Felodipine Event Reduction (FEVER) trial. J Hypertens 2010;28: 2016-2025.
8. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985;291:97-104.
9. Hypertension, Detection and Follow-up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5-year findings of the Hypertension Detection and Follow-up Program. Hypertension 1984;6(Suppl I):I198-I206.
10. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762. (Pubitemid 28269185)
11. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G; Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374:525-533.
12. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry M, Prineas R, Schron E (The INDANA Investigators). Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med 1997;126:761-767. (Pubitemid 27209641)
13. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, Perkovic V, Li N, MacMahon S; Blood Pressure Lowering Treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008;29:2669-2680.
14. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, Forette F. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349-1354. (Pubitemid 15060905)
15. Coope J,Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986;293:1145-1151. (Pubitemid 16008923)
16. SHEP Collaborative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991;265:3255-3264.
17. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T,Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-1285.
18. MRCWorking Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-412.
19. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764. (Pubitemid 27387202)
20. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998;16: 1823-1829. (Pubitemid 28548522)
21. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886. (Pubitemid 36677151)
22. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358: 1887-1898. (Pubitemid 351620109)
23. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585.
24. The Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in MICROHOPE substudy. Lancet 2000;355:253-259.
25. ADVANCE Collaboration Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007;370:829-840.
26. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
27. Yusuf S, Diener H-C, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlö f B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group., for the PROFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:225-237.
28. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338: 1665-1683.
29. Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005;112:3384-3390.
30. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J 2010;31:2837-2840.
31. Asia Pacific Cohort Studies Collaboration. Systolic blood pressure, diabetes and the risk of cardiovascular disease in the Asia-Pacific region. J Hypertens 2007;25: 1205-1213.